A phase II trial of the epothilone B analog ixabepilone (BMS-247550) in patients with metastatic melanoma.
<h4>Background</h4>Ixabepilone (BMS-247550), an epothilone B analog, is a microtubule stabilizing agent which has shown activity in several different tumor types and preclinical models in melanoma. In an open label, one-arm, multi-center phase II trial the efficacy and toxicity of this e...
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2010-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0008714&type=printable |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849695239483162624 |
|---|---|
| author | Patrick A Ott Anne Hamilton Amanda Jones Naomi Haas Tsiporah Shore Sandra Liddell Paul J Christos L Austin Doyle Michael Millward Franco M Muggia Anna C Pavlick |
| author_facet | Patrick A Ott Anne Hamilton Amanda Jones Naomi Haas Tsiporah Shore Sandra Liddell Paul J Christos L Austin Doyle Michael Millward Franco M Muggia Anna C Pavlick |
| author_sort | Patrick A Ott |
| collection | DOAJ |
| description | <h4>Background</h4>Ixabepilone (BMS-247550), an epothilone B analog, is a microtubule stabilizing agent which has shown activity in several different tumor types and preclinical models in melanoma. In an open label, one-arm, multi-center phase II trial the efficacy and toxicity of this epothilone was investigated in two different cohorts: chemotherapy-naïve (previously untreated) and previously treated patients with metastatic melanoma.<h4>Methodology/principal findings</h4>Eligible patients had histologically-confirmed stage IV melanoma, with an ECOG performance status of 0 to 2. Ixabepilone was administered at a dose of 20 mg/m(2) on days 1, 8, and 15 during each 28-day cycle. The primary endpoint was response rate (RR); secondary endpoints were time to progression (TTP) and toxicity. Twenty-four patients were enrolled and 23 were evaluable for response. Initial serum lactate dehydrogenase (LDH) levels were elevated in 6/11 (55%) of the previously treated and in 5/13 (38%) of the previously untreated patients. No complete or partial responses were seen in either cohort. One patient in the previously treated group developed neutropenia and fatal septic shock. Seventeen patients (8 in the previously untreated group and 9 in the previously treated group) progressed after 2 cycles, whereas six patients (3 in each group) had stable disease after 2-6 cycles. Median TTP was 1.74 months in the previously untreated group (95% CI = 1.51 months, upper limit not estimated) and 1.54 months in the previously treated group (95% CI = 1.15 months, 2.72 months). Grade 3 and/or 4 toxicities occurred in 5/11 (45%) of previously untreated and in 5/13 (38%) of previously treated patients and included neutropenia, peripheral neuropathy, fatigue, diarrhea, and dyspnea.<h4>Conclusions/significance</h4>Ixabepilone has no meaningful activity in either chemotherapy-naïve (previously untreated) or previously treated patients with metastatic melanoma. Further investigation with ixabepilone as single agent in the treatment of melanoma is not warranted.<h4>Trial registration</h4>Clinical Trials.gov NCT00036764. |
| format | Article |
| id | doaj-art-bcaa7301c3184c05ad9a4660ad8a3bc0 |
| institution | DOAJ |
| issn | 1932-6203 |
| language | English |
| publishDate | 2010-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj-art-bcaa7301c3184c05ad9a4660ad8a3bc02025-08-20T03:19:50ZengPublic Library of Science (PLoS)PLoS ONE1932-62032010-01-0151e871410.1371/journal.pone.0008714A phase II trial of the epothilone B analog ixabepilone (BMS-247550) in patients with metastatic melanoma.Patrick A OttAnne HamiltonAmanda JonesNaomi HaasTsiporah ShoreSandra LiddellPaul J ChristosL Austin DoyleMichael MillwardFranco M MuggiaAnna C Pavlick<h4>Background</h4>Ixabepilone (BMS-247550), an epothilone B analog, is a microtubule stabilizing agent which has shown activity in several different tumor types and preclinical models in melanoma. In an open label, one-arm, multi-center phase II trial the efficacy and toxicity of this epothilone was investigated in two different cohorts: chemotherapy-naïve (previously untreated) and previously treated patients with metastatic melanoma.<h4>Methodology/principal findings</h4>Eligible patients had histologically-confirmed stage IV melanoma, with an ECOG performance status of 0 to 2. Ixabepilone was administered at a dose of 20 mg/m(2) on days 1, 8, and 15 during each 28-day cycle. The primary endpoint was response rate (RR); secondary endpoints were time to progression (TTP) and toxicity. Twenty-four patients were enrolled and 23 were evaluable for response. Initial serum lactate dehydrogenase (LDH) levels were elevated in 6/11 (55%) of the previously treated and in 5/13 (38%) of the previously untreated patients. No complete or partial responses were seen in either cohort. One patient in the previously treated group developed neutropenia and fatal septic shock. Seventeen patients (8 in the previously untreated group and 9 in the previously treated group) progressed after 2 cycles, whereas six patients (3 in each group) had stable disease after 2-6 cycles. Median TTP was 1.74 months in the previously untreated group (95% CI = 1.51 months, upper limit not estimated) and 1.54 months in the previously treated group (95% CI = 1.15 months, 2.72 months). Grade 3 and/or 4 toxicities occurred in 5/11 (45%) of previously untreated and in 5/13 (38%) of previously treated patients and included neutropenia, peripheral neuropathy, fatigue, diarrhea, and dyspnea.<h4>Conclusions/significance</h4>Ixabepilone has no meaningful activity in either chemotherapy-naïve (previously untreated) or previously treated patients with metastatic melanoma. Further investigation with ixabepilone as single agent in the treatment of melanoma is not warranted.<h4>Trial registration</h4>Clinical Trials.gov NCT00036764.https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0008714&type=printable |
| spellingShingle | Patrick A Ott Anne Hamilton Amanda Jones Naomi Haas Tsiporah Shore Sandra Liddell Paul J Christos L Austin Doyle Michael Millward Franco M Muggia Anna C Pavlick A phase II trial of the epothilone B analog ixabepilone (BMS-247550) in patients with metastatic melanoma. PLoS ONE |
| title | A phase II trial of the epothilone B analog ixabepilone (BMS-247550) in patients with metastatic melanoma. |
| title_full | A phase II trial of the epothilone B analog ixabepilone (BMS-247550) in patients with metastatic melanoma. |
| title_fullStr | A phase II trial of the epothilone B analog ixabepilone (BMS-247550) in patients with metastatic melanoma. |
| title_full_unstemmed | A phase II trial of the epothilone B analog ixabepilone (BMS-247550) in patients with metastatic melanoma. |
| title_short | A phase II trial of the epothilone B analog ixabepilone (BMS-247550) in patients with metastatic melanoma. |
| title_sort | phase ii trial of the epothilone b analog ixabepilone bms 247550 in patients with metastatic melanoma |
| url | https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0008714&type=printable |
| work_keys_str_mv | AT patrickaott aphaseiitrialoftheepothilonebanalogixabepilonebms247550inpatientswithmetastaticmelanoma AT annehamilton aphaseiitrialoftheepothilonebanalogixabepilonebms247550inpatientswithmetastaticmelanoma AT amandajones aphaseiitrialoftheepothilonebanalogixabepilonebms247550inpatientswithmetastaticmelanoma AT naomihaas aphaseiitrialoftheepothilonebanalogixabepilonebms247550inpatientswithmetastaticmelanoma AT tsiporahshore aphaseiitrialoftheepothilonebanalogixabepilonebms247550inpatientswithmetastaticmelanoma AT sandraliddell aphaseiitrialoftheepothilonebanalogixabepilonebms247550inpatientswithmetastaticmelanoma AT pauljchristos aphaseiitrialoftheepothilonebanalogixabepilonebms247550inpatientswithmetastaticmelanoma AT laustindoyle aphaseiitrialoftheepothilonebanalogixabepilonebms247550inpatientswithmetastaticmelanoma AT michaelmillward aphaseiitrialoftheepothilonebanalogixabepilonebms247550inpatientswithmetastaticmelanoma AT francommuggia aphaseiitrialoftheepothilonebanalogixabepilonebms247550inpatientswithmetastaticmelanoma AT annacpavlick aphaseiitrialoftheepothilonebanalogixabepilonebms247550inpatientswithmetastaticmelanoma AT patrickaott phaseiitrialoftheepothilonebanalogixabepilonebms247550inpatientswithmetastaticmelanoma AT annehamilton phaseiitrialoftheepothilonebanalogixabepilonebms247550inpatientswithmetastaticmelanoma AT amandajones phaseiitrialoftheepothilonebanalogixabepilonebms247550inpatientswithmetastaticmelanoma AT naomihaas phaseiitrialoftheepothilonebanalogixabepilonebms247550inpatientswithmetastaticmelanoma AT tsiporahshore phaseiitrialoftheepothilonebanalogixabepilonebms247550inpatientswithmetastaticmelanoma AT sandraliddell phaseiitrialoftheepothilonebanalogixabepilonebms247550inpatientswithmetastaticmelanoma AT pauljchristos phaseiitrialoftheepothilonebanalogixabepilonebms247550inpatientswithmetastaticmelanoma AT laustindoyle phaseiitrialoftheepothilonebanalogixabepilonebms247550inpatientswithmetastaticmelanoma AT michaelmillward phaseiitrialoftheepothilonebanalogixabepilonebms247550inpatientswithmetastaticmelanoma AT francommuggia phaseiitrialoftheepothilonebanalogixabepilonebms247550inpatientswithmetastaticmelanoma AT annacpavlick phaseiitrialoftheepothilonebanalogixabepilonebms247550inpatientswithmetastaticmelanoma |